NICE recommends Lilly’s migraine med Emgality
CGRP antagonist approved to prevent migraine in adults with episodic and chronic migraine
Read More
Tag: Emgality
Emgality ‘CONQUER’s in late-stage migraine trial
Treatment with Emgality reduced monthly migraine headache days by 4.1 days.
Read More
FDA ‘yes’ for Emgality in cluster headache
In a trial, patients taking Emgality experienced 8.7 fewer weekly cluster headache attacks than they did at baseline.
Read More
European Commission approves Lilly’s Emgality for migraine
Eli Lilly has confirmed that Emgality, a once-monthly monoclonal antibody injection, has been approved by the European Commission for preventive treatment of migraine in adults who have at least four migraine days per month.
Read More
Lilly files lasmiditan for migraine
Eli Lilly has filed an application in the US to market lasmiditan for the acute treatment of migraine with or without aura in adults.
Read More
Lilly’s Emgality wins first nod for migraine prevention
The US Food and Drug Administration have green-lighted use of Eli Lilly’s non-opioid pain drug Emgality for the prevention of migraine.
Read More
CHMP puts 13 therapies forward for EU approval
Marking a bumper month for Committee for Medicinal Products for Human Use (CHMP) decisions, 13 medicines have been put forward for approval in the region, including three orphan medicines.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
